Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr;5(2):67-75.
doi: 10.1177/1759720X12470752.

Personalized medicine for osteoarthritis: where are we now?

Allen Dale Sawitzke  1
Affiliations

Personalized medicine for osteoarthritis: where are we now?

Allen Dale Sawitzke. Ther Adv Musculoskelet Dis. 2013 Apr.

Abstract

Personalized medicine is a much talked about subject that is a timely and important development to healthcare in general and also specifically for patients affected by osteoarthritis. This review uses biomarker examples pertinent to osteoarthritis to highlight the current status of the field, while also highlighting probable future developments. It is not meant to be an exhaustive account. The BIPED(s) [Burden of disease, Investigative, Prognosis, Efficacy, Diagnosis (safety)] classification system is used to organize the discussion of examples. Biomarkers pertaining to burden, investigation, prognosis, efficacy, diagnosis and safety are highlighted. The examples are followed by a discussion of issues related to interpretation and application of biomarker results and approaches to solve the challenges interpretation faces, including graphical, mathematical and synthetic representations. Through this review, it is hoped that a better appreciation can be gained of the potential and pitfalls of personal medicine in the care of patients with osteoarthritis.

Keywords: analysis; biomarker; diagnosis; efficacy; human; investigation; osteoarthritis; prognosis; safety.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare no conflicts of interest in preparing this article.

Figures

Figure 1.
Figure 1.
Likelihood of developing severe osteoarthritis based on a gene marker of interleukin 1 receptor antagonist. (IL1RN). Reproduced from Attur et al. [2010] with permission from BMJ Publishing Group Ltd.
Figure 2.
Figure 2.
Cyclooxygenase 2 genotypes and response of dental pain to selected nonsteroidal anti-inflammatory drugs. Reproduced from Lee et al. [2006].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Armstrong D., Brouillard D., Matangi M. (2011) The effect of the change in the Framingham Risk Score calculator between the 2006 and 2009 Canadian lipid guidelines. Can J Cardiol 27: 67–170 - PubMed
    1. Aronow W., Banach M. (2012) Ten most important things to learn from the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Blood Press 21: 3–5 - PubMed
    1. Attur M., Wang H., Kraus V., Bukowski J., Aziz N., Krasnokutsky S., et al. (2010) Radiographic severity of knee osteoarthritis is conditional on interleukin 1 receptor antagonist gene variations. Ann Rheum Dis 69: 856–861 - PMC - PubMed
    1. Bauer D., Hunter D., Abramson S., Attur M., Corr M., Felson D., et al. (2006) Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 14: 723–727 - PubMed
    1. Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69: 89–95 - PubMed

LinkOut - more resources